Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

February 25, 2021February 25, 2021

Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early

News

Understanding the molecular components of odors used by trained dogs to detect prostate cancer could help researchers to develop computers with similar diagnostic accuracy, a new study shows. The study, ... Read more

January 21, 2021January 21, 2021

Daily Coffee Drinking Lowers Prostate Cancer Risk, Study Suggests

News

Drinking more coffee may significantly reduce a person’s risk of prostate cancer, with a nearly 1% lesser likelihood seen with each additional daily cup of coffee consumed, an analysis of ... Read more

January 5, 2021January 5, 2021

Long-term ADT Found to Raise Risk of Cardiovascular Death

News

Long-term exposure to androgen deprivation therapy (ADT), a common treatment for prostate cancer, is associated with worse cardiorespiratory fitness and a higher risk of cardiovascular death, a new study reports. ... Read more

December 15, 2020December 15, 2020

Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells

News

Researchers have developed a new technology that can be used to deliver the gene-editing tool CRISPR/Cas9 into prostate cancer cells without the need for viral vectors, a proof-of-concept study demonstrates. ... Read more

November 17, 2020November 17, 2020

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

News

An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug ... Read more

November 10, 2020November 10, 2020

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

News

The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a positive ... Read more

October 29, 2020October 29, 2020

FDA Clears Ezra Prostate AI, a First for Cancer Imaging

News

The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the efficiency with which radiologists analyze images of the prostate ... Read more

October 1, 2020October 1, 2020

Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows

News

Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care ... Read more

August 31, 2020August 31, 2020

FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies

News

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx, a blood test that can be used to identify cancer patients who may benefit from certain targeted therapies, including ... Read more

August 18, 2020August 18, 2020

Google AI System Outperforms General Pathologists in Grading Prostate Cancers, Study Finds

News

A novel artificial intelligence (AI) technology developed by Google is better at grading prostate cancer biopsies than general pathologists and is as good at identifying cancerous samples, a new study reports. ... Read more